Condition: Hidradenitis Suppurativa (HS) · Sponsor: Citryll BV
The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS. Participants will: Take receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period
This description comes directly from the study's public registry record.
Leonie M Middelink · +31613328444 · lmiddelink@citryll.com
Always discuss trial participation with your own doctor first.
| CA-01 | Barrie, Canada | Recruiting |
| CA-05 | Calgary, Canada | Recruiting |
| CA-02 | London, Canada | Recruiting |
| CA-04 | Newmarket, Canada | Recruiting |
| CA-03 | Winnipeg, Canada | Recruiting |
| DE-06 | Bad Bentheim, Germany | Recruiting |
| DE-01 | Bochum, Germany | Recruiting |
| DE-04 | Dresden, Germany | Recruiting |
| DE-02 | Frankfurt, Germany | Recruiting |
| DE-08 | Kiel, Germany | Recruiting |
| DE-03 | Oldenburg, Germany | Recruiting |
| Erasmus UMC | Rotterdam, Netherlands | Recruiting |
+ 16 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06993233